INCY - Incyte rises 5% as company raises Jakafi net product revenues
- Incyte ( NASDAQ: INCY ) is trading ~5% higher after the company raised 2022 Jakafi net product revenues.
- The company tightened its full year 2022 guidance of chronic GVHD treatment Jakafi net product revenues to be $2.38B - $2.40B from prior outlook of $2.36B - $2.40B.
- While other Hematology/Oncology net product revenues to $200M - $210M from prior outlook of $210M - $240M.
- Quarterly revenue rose 1.2% Y/Y to $823.03M, but missed by $20.62M.
- Q3 Non-GAAP EPS of $0.60 missed estimates by $0.10.
- Quarterly Jakafi revenue rose 13.2% Y/Y to $619.6M.
- INCY posted Opzelura net product revenues of $38M, driven by robust demand and broadening payer access.
- Presentation , Transcript
For further details see:
Incyte rises 5% as company raises Jakafi net product revenues